Medera receives FDA clearance for a first-in-human gene therapy trial for heart failure with preserved ejection fraction

Press/Media

Period	21 Nov 2022

Media coverage

Title	Medera receives FDA clearance for a first-in-human gene therapy trial for heart failure with preserved ejection fraction
Media name/outlet	PipelineReview
Country/Territory	Spain
Date	21/11/22
URL	www.pipelinereview.com/index.php/2022112182097/DNA-RNA-and-Cells/Medera-receives-FDA-clearance-for-a-first-in-human-gene-therapy-trial-for-heart-failure-with-preserved-ejection-fraction.html
Persons	Roger Hajjar,